Valeo Foods Group Acquires Leading Italian Bakery Company Dal Colle
29.5.2024 13:05:00 EEST | Business Wire | Press release
Valeo Foods Group (“Valeo Foods” or “The Group”), one of Europe’s leading producers of quality sweets, treats and snacks, has completed the process to acquire assets of a renowned Italian producer of high-quality bakery products, Dal Colle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529721501/en/
Ronald Kers, CEO of Valeo Foods Group (Photo: Business Wire)
With a history and heritage dating back 120 years, Dal Colle produces a range of bakery products, sweet treats and snacks for every occasion including Pandori, Panettoni and Croissants. Its range of over 180 products is currently sold in over 35 countries around the world.
Dal Colle provides a highly complementary addition to Valeo’s expanding Italian platform and operations, built on its initial acquisition of Balconi in 2015 and the subsequent acquisitions of Val D’Enza in 2017 and IDP Pattini in 2023.
Ronald Kers, CEO of Valeo Foods Group, said: "Dal Colle is a fantastic addition to the Valeo Foods portfolio which already boasts many of Europe’s finest and most established brands, with deep heritage and connections with consumers. On a commercial level it diversifies and strengthens our product offering and completes our range of quality confectionary and sweet treats in this market, ranging from iconic sponge cakes to wafers and biscuits. It also adds considerable new manufacturing and logistical capabilities to our Italian platform, which will support our growth ambitions in Italy and across Europe. This is very consistent with our vision to position Valeo Foods as the undisputed European sweet treats champion.”
Alberto Alfieri, CEO of Valeo Foods Italy & President of Balconi Spa, said: “We have long admired Dal Colle who share our passion for delivering high-quality products to consumers and their heritage range and operational footprint are highly complementary to Valeo Foods Italy and the Balconi business. We very much look forward to welcoming close to 90 new colleagues to our team and work with them to accelerate the growth of our enlarged Italian business.”
Valeo Foods Group is one of Europe’s fastest growing food groups and one of Europe’s leading producers and purveyors of quality sweets, treats and snacks.
With revenues in excess of €1.5 billion, the Valeo Foods portfolio includes over 80 brands enjoyed by customers in over 106 countries around the world including Balconi, Carstens, Jacobs, Barrat, Fox’s Mints, Taveners, Poppets, Rowse Honey and Maple Crest. The Group employs over 4,500 people across 30 manufacturing facilities and offices in the UK, Italy, Germany, the Netherlands, Ireland, the Czech Republic and Canada. Valeo Foods Group is owned by leading global investment firm Bain Capital.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529721501/en/
Contact information
Media Enquiries on behalf of Valeo Foods Group:
Robert Brown, Associate Partner, Reputation Inc
rbrown@reputation-inc.com
+353 85 725 2626
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom